Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOFH1M)

Drug Name
Volasertib Drug Info
Synonyms
Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
Cross-matching ID
PubChem CID
10461508
CAS Number
CAS 755038-65-4
TTD Drug ID
D00BYM

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Bacterial invasion of epithelial cells 1.89 0.00e+0 59/77 (76.62%) CAV1;CDH1;CRK;...
Spinocerebellar ataxia 1.82 3.13e-2 128/143 (89.51%) SLC25A4;PSMD12;PUM1;...
Adherens junction 1.80 4.58e-2 63/71 (88.73%) CDH1;FYN;ACTN4;...
Progesterone-mediated oocyte maturation 1.79 3.44e-2 75/100 (75%) PLK1;AURKA;CCNB2;...
Arrhythmogenic right ventricular cardiomyopathy 1.78 3.00e-2 70/77 (90.91%) ITGA6;DAG1;ITGB3;...
Regulation of actin cytoskeleton 1.75 4.17e-2 185/218 (84.86%) ITGA6;ACTN4;CRK;...
Oocyte meiosis 1.74 4.11e-2 90/129 (69.77%) CDC20;PLK1;AURKA;...
Asthma -1.61 4.34e-2 25/31 (80.65%) HLA-DMB;HLA-DOB;HLA-DRA;...
Fanconi anemia pathway -1.61 4.56e-2 36/54 (66.67%) BRIP1;CENPX;RMI1;...
Retinol metabolism -1.61 4.60e-2 41/68 (60.29%) UGT2B4;CYP2C18;UGT2B15;...
Pyrimidine metabolism -1.64 3.62e-2 40/56 (71.43%) UMPS;CTPS2;CMPK1;...
Base excision repair -1.65 3.11e-2 29/33 (87.88%) POLE3;MUTYH;PARP4;...
Viral protein interaction with cytokine and cytokine re... -1.70 1.72e-2 84/100 (84%) IL6;CCL21;IL20RA;...
Complement and coagulation cascades -1.71 1.48e-2 76/85 (89.41%) C8A;CFI;CFD;...
Steroid hormone biosynthesis -1.72 1.59e-2 43/61 (70.49%) CYP11B2;UGT2B4;SRD5A1;...
Systemic lupus erythematosus -1.73 1.36e-2 45/135 (33.33%) C2;SNRPD3;HLA-DMB;...
Pertussis -1.73 1.47e-2 64/76 (84.21%) CASP1;TRAF6;ITGAM;...
Nucleotide excision repair -1.76 1.11e-2 40/47 (85.11%) ERCC1;RPA2;POLE;...
Type I diabetes mellitus -1.77 1.23e-2 38/43 (88.37%) HLA-DMB;ICA1;HLA-DOB;...
Pentose and glucuronate interconversions -1.79 9.37e-3 17/34 (50%) UGP2;UGT2B4;UGT2B15;...
Graft-versus-host disease -1.80 9.58e-3 32/42 (76.19%) HLA-DMB;HLA-DOB;HLA-DRA;...
Staphylococcus aureus infection -1.84 9.85e-3 72/95 (75.79%) KRT14;HLA-DOB;KRT23;...
Metabolism of xenobiotics by cytochrome P450 -1.93 1.28e-3 49/77 (63.64%) GSTM2;UGT2B4;GSTA3;...
Tyrosine metabolism -1.96 1.53e-3 30/36 (83.33%) TH;HPD;DCT;...
One carbon pool by folate -1.96 1.92e-3 15/20 (75%) ALDH1L1;DHFR;MTHFS;...
Mismatch repair -1.96 2.55e-3 22/23 (95.65%) RPA2;EXO1;LIG1;...
Drug metabolism -2.37 0.00e+0 78/151 (51.66%) GSTM2;UGT2B4;CES2;...
DNA replication -2.56 0.00e+0 34/36 (94.44%) RPA2;POLE;LIG1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H